Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres
Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres
Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.
Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Bin Rias I, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12:217–26.
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–7.
Saba N, Abraham R, Keating A. Overview of autologous stem cell transplantation. Crit Rev Oncol Hematol. 2000;36:27–48.
Ljungman P, Bregni M, Brune M, de Witte T, Dini G, Einsele H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219–34.
Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9.
Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–56.
Peters WP, Dansey R, Baynes RD. Autologous bone marrow and stem cell transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Holland-Frei Cancer Medicine. B.C. Decker; 2003.
Champlin R. Hematopoietic cellular transplantation. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Holland-Frei Cancer Medicine. B.C. Decker; 2003.
Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15:18–25.
Miller CB, Piantadosi S, Vogelsang GB, Marcellus DC, Grochow L, Kennedy MJ, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327–32.
Blume KG, Thomas ED. A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:1–12.
Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52:1367–71.
Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29:1980–6.
Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, et al. Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation. Haematologica. 2014;99:908–15.
Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, et al. CLL subcommittee, Chronic Malignancies Working Party. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2017;178:521–33.
Royal Decree amending article 20, § 1, a), of the annex to the Royal Decree of 14 September 1984 establishing the nomenclature of health care benefits, on compulsory insurance for health care and allowances. Belgisch Staatsblad / Moniteur Belge; 2012-12-06/09.
Haematological malignancies in Belgium, Belgian Cancer Registry, Brussels 2015.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120:1398–408.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
Andersen PK, Klein JP, Rosthøj S. Generalised linear models for correlated pseudo-observations, with applications to multi-state models. Biometrika. 2003;90:15–27.
Logan BR. Review of multistate models in hematopoietic cell transplantation studies. Biol Blood Marrow Transplant. 2013;19:S84–S87.
Hurvich CM, Tasi C-L. Regression and time series model selection in small samples. Biometrika. 1989;ume 76(Issue 2):297–330.
Logan BR, Nelson GO, Klein JP. Analyzing center specific outcomes in hematopoietic cell transplantation. Lifetime Data Anal. 2008;14:389–404.
Anthias C, Ethell ME, Potter MN, Madrigal A, Shaw BE. The impact of improved JACIE standards on the care of related BM and PBSC donors. Bone Marrow Transplant. 2015;50:244–7.
Anthias C, O’Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, et al. European Group for Blood and Marrow Transplantation Centers with FACT-JACIE accreditation have significantly better compliance with related donor care standards. Biol Blood Marrow Transplant. 2016;22:514–9.
Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP); EBMT Paediatric Working Party (PWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); EBMT (JACIE). Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742–55.
Horowitz MM, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood. 1992;79:2771–4.
Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant. 1993;12:371–80.
Matsuo K, Hamajima N, Morishima Y, Harada M. Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for hematopoietic cell transplantation. Bone Marrow Transplant. 2000;26:1061–7.
Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000;355:1393–8.
Loberiza FR Jr., Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003;31:417–21.
LeMaistre CF, Loberiza FR Jr. What is quality in a transplant program? Biol Blood Marrow Transplant. 2005;11:241–6.
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, et al. Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) and the European Leukemia Net (ELN). Economics and outcome after hematopoietic stem cell transplantation: a retrospective cohort study. EBioMedicine. 2015;2:2101–9.
